0000905718-18-000190.txt : 20180214 0000905718-18-000190.hdr.sgml : 20180214 20180214150119 ACCESSION NUMBER: 0000905718-18-000190 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 GROUP MEMBERS: ABINGWORTH BIOVENTURES VI, LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81821 FILM NUMBER: 18611373 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Abingworth LLP CENTRAL INDEX KEY: 0001397144 IRS NUMBER: 980518585 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 (0)20 7534 1500 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN SC 13G/A 1 paratek13gam2dec312017.htm SC 13G/A

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

Paratek Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
699374302
(CUSIP Number)
December 31, 2017
(Date of Event which Requires Filing of this Statement)
 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 
[   ] Rule 13d-1(b)
[   ] Rule 13d-1(c)
[X] Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Cusip No. 699374302



1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Abingworth LLP

98-051-8585

  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a) [   ]
  (b) [   ]
3

SEC USE ONLY

  

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

England

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

 

  0 
6

SHARED VOTING POWER

 

1,041,131*
7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

 

1,041,131*
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,041,131*

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

[   ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

3.7%*

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IA

             

 * Based on the information set forth in the Quarterly Report on Form 10-Q of Paratek Pharmaceuticals, Inc. (the “Issuer”) filed with the Securities and Exchange Commission on November 8, 2017, there were 27,941,015 shares of the Issuer’s common stock, par value $0.001 (the “Common Stock”), outstanding as of October 31, 2017. As of December 31, 2017 (the “Event Date”), Abingworth LLP (“Abingworth”) may be deemed to beneficially own an aggregate of 1,041,131 shares of Common Stock of the Issuer. The number of shares of Common Stock reported above consists of 1,041,131 shares of Common Stock held by Abingworth Bioventures VI, LP (“ABV VI”). Abingworth, as the investment manager of ABV VI, may be deemed to beneficially own the 1,041,131 shares of Common Stock held by ABV VI. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 3.7% of the shares of Common Stock deemed issued and outstanding. This Amendment No. 2 constitutes an exit filing for the Reporting Persons as the Reporting Persons beneficially own less than five percent (5%) of the Common Shares of Issuer.  

   

Cusip No. 699374302



1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Abingworth Bioventures VI, LP

  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a) [   ]
  (b) [   ]
3

SEC USE ONLY 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

England

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

5

SOLE VOTING POWER

 

  0 
6

SHARED VOTING POWER

 

1,041,131*
7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

 

1,041,131*
9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,041,131*

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

[   ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

3.7%*

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IA

             

 * Based on the information set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on November 8, 2017, there were 27,941,015 shares of Common Stock, par value $0.001, outstanding as of October 31, 2017. As of the Event Date, ABV VI held 1,041,131 shares of Common Stock of the Issuer. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, ABV VI may be deemed to beneficially own 3.7% of the shares of Common Stock deemed issued and outstanding. Abingworth, as the investment manager of ABV VI, may be deemed to beneficially own the 1,041,131 shares of Common Stock held by ABV VI. This Amendment No. 2 constitutes an exit filing for the Reporting Persons as the Reporting Persons beneficially own less than five percent (5%) of the Common Shares of Issuer.

 
 

 

Item 1(a).   Name of Issuer:

 

Paratek Pharmaceuticals, Inc.

 

Item 1(b).   Address of Issuer’s Principal Executive Offices:

 

75 Park Plaza

Boston, MA 02116

 

Item 2(a).   Name of Persons Filing:

 

This Schedule 13G is being filed on behalf of (i) Abingworth Bioventures VI, LP (“ABV VI”), and (ii) Abingworth LLP (“Abingworth” and together with ABV VI, the “Reporting Persons”). As of December 31, 2017 (the “Event Date”), ABV VI is the owner of record of 1,041,131 shares of common stock (the “Common Stock”) of Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). Abingworth, as the investment manager of ABV VI, may be deemed to beneficially own the 1,041,131 shares of Common Stock held by ABV VI.

 

Item 2(b).   Address of Principal Business Office or, if None, Residence:

 

The business address for Abingworth and ABV VI is Princess House, 38 Jermyn Street, London, England SW1Y 6DN.

 

Item 2(c).   Citizenship:

 

Abingworth LLP is a limited liability partnership organized under the laws of England. ABV VI is a limited partnership organized under the laws of England.

  

Item 2(d). Title of Class of Securities:

 

Common Stock, par value $0.001

 

Item 2(e). CUSIP Number:

 

699374302

  

Item 3.   If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

 

Not Applicable.

 

 
 

 

Item 4. Ownership.  
 

As reported in the cover pages to this report, the ownership information with respect to each of the Reporting Persons is as follows:

 

 
  (a)  Amount Beneficially Owned: 1,041,131*    
  (b)  Percent of Class: 3.7%*    
  (c)  Number of Shares as to which such person has:      
  (i)  Sole power to vote or to direct the vote: 0    
  (ii)  Shared power to vote or to direct the vote: 1,041,131*  
  (iii)  Sole power to dispose or to direct the disposition of:    
  (iv)  Shared power to dispose or to direct the disposition of: 1,041,131*  
           

* Based on the information set forth in the Quarterly Report on Form 10-Q of Paratek Pharmaceuticals, Inc. (the “Issuer”) filed with the Securities and Exchange Commission on November 8, 2017, there were 27,941,015 shares of the Issuer’s common stock, par value $0.001 (the “Common Stock”), outstanding as of October 31, 2017. As of December 31, 2017 (the “Event Date”), Abingworth LLP (“Abingworth”) may be deemed to beneficially own an aggregate of 1,041,131 shares of Common Stock of the Issuer. The number of shares of Common Stock reported above consists of 1,041,131 shares of Common Stock held by Abingworth Bioventures VI, LP (“ABV VI”). Abingworth, as the investment manager of ABV VI, may be deemed to beneficially own the 1,041,131 shares of Common Stock held by ABV VI. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 3.7% of the shares of Common Stock deemed issued and outstanding. This Amendment No. 2 constitutes an exit filing for the Reporting Persons as the Reporting Persons beneficially own less than five percent (5%) of the Common Shares of Issuer.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

  

Item 10. Certification.

 

Not Applicable.

  

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2018

 

   
ABINGWORTH LLP  
   
   
By: /s/ John Heard  
  Name:  John Heard  
  Title:  Authorized Signatory  
   
   
ABINGWORTH BIOVENTURES VI, LP  
   
By: Abingworth LLP, its Manager  
   
   
By: /s/ John Heard  
  Name:  John Heard  
  Title:  Authorized Signatory  
   
   

 

Attention: Intentional misstatements or omissions of fact constitute

Federal criminal violations (See 18 U.S.C. 1001)

 

 

 
 

 

 

Exhibit Index

 

Exhibit

A. Joint Filing Agreement dated as of February 16, 2016 by and between Abingworth LLP and Abingworth Bioventures VI, LP (incorporated by reference to Exhibit A to Schedule 13G, filed with the Securities and Exchange Commission on February 16, 2016)